ArticleFrontiers in oncology2026
Application of remimazolam anesthesia in elderly patients undergoing radical resection for colorectal cancer: a cohort study on gastrointestinal recovery and complication rates.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Optimizing anesthesia within the enhanced recovery after surgery (ERAS) protocol was crucial for elderly patients undergoing radical resection for colorectal cancer. This study aimed to assess the impact of remimazolam versus propofol anesthesia on postoperative gastrointestinal function recovery and complication rates in this population. Methods: This prospective cohort study included elderly patients who underwent radical cancer resection from January 2023 to January 2025. Patients were assigned to either the remimazolam group or the propofol group based on the anesthetic used. Gastrointestinal hormones were measured preoperatively and 24 hours postoperatively. Recovery times for bowel sounds, first flatus, first defecation, and first solid food intake were recorded. Postoperative complications, including nausea/vomiting and delirium, were monitored, and recovery quality was assessed using the QoR-15 scale one week postoperatively. Results: After propensity score matching, 243 patients were analyzed (remimazolam: n=115; propofol: n=128). At 24 hours postoperatively, motilin (81.47 ± 5.13 pg/mL vs. 79.61 ± 5.62 pg/mL, P = 0.008) and gastrin levels (48.25 ± 5.88 pg/mL vs. 42.72 ± 6.41 pg/mL) were higher in the remimazolam group. The remimazolam group showed shorter gastrointestinal recovery times (all P<0.05). Nausea/vomiting (5.22% vs. 13.28%, P = 0.032) and delirium (10.43% vs. 21.88%, P = 0.016) rates were lower, and QoR-15 scores were higher (125.44 ± 9.95 vs. 119.89 ± 12.82, P<0.001) compared to the propofol group. Conclusion: For elderly patients undergoing colorectal cancer surgery within an ERAS pathway, remimazolam anesthesia was associated with shorter gastrointestinal recovery times, lower observed rates of selected postoperative complications, and higher QoR-15 scores compared with propofol. Given the prospective cohort design, these findings should be interpreted as associations rather than evidence of causality and require confirmation in randomized studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.